Sqz Competitors

Delisted . USA . 
Stock . Sqz Biotechnologies Co
SQZDelisted Stock  USD 0.10  0.04  28.57%   
Sqz Biotechnologies competes with AN2 Therapeutics, Inhibikase Therapeutics, Pmv Pharmaceuticals, Anebulo Pharmaceuticals, and SAB Biotherapeutics; as well as few others. The company runs under Biotechnology sector within Health Care industry. Analyzing Sqz Biotechnologies competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Sqz Biotechnologies to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in producer price index.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Sqz Biotechnologies competition on your existing holdings.
  
Specify up to 10 symbols:
Hype
Prediction
LowEstimatedHigh
0.100.100.10
Details
Intrinsic
Valuation
LowRealHigh
0.100.10.10
Details

Sqz Biotechnologies Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Sqz Biotechnologies and its competitors represents the degree of relationship between the price movements of corresponding delisted stocks. A correlation of about +1.0 implies that the price of Sqz and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Sqz Biotechnologies does not affect the price movement of the other competitor.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio
High positive correlations   
PMVP
+ 0.87
IKT
IKT
+ 0.86
MIRO
FRTX
+ 0.8
IKT
PMVP
+ 0.76
MIRO
FRTX
+ 0.76
MIRO
FRTX
+ 0.76
PMVP
  
High negative correlations   
PCSA
- 0.65
MIRO
ANEB
- 0.6
MIRO
FRTX
- 0.58
ANEB
FRTX
- 0.55
PCSA
PCSA
- 0.54
IKT
ANEB
- 0.54
IKT

Risk-Adjusted Indicators

There is a big difference between Sqz Stock performing well and Sqz Biotechnologies Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Sqz Biotechnologies' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
ANTX  1.86  0.19  0.06  0.34  1.86 
(3.09)
 3.73 
(3.42)
 28.03 
MIRO  4.85  0.38  0.05  0.94  5.26 
(6.37)
 11.73 
(8.87)
 38.49 
IKT  4.73  1.03  0.20  0.73  4.76 
(5.60)
 14.93 
(9.09)
 37.40 
PMVP  1.55 (0.03)(0.03) 0.07  1.99 
(1.87)
 3.75 
(3.64)
 13.98 
ANEB  5.00 (0.35) 0.00 (0.12) 0.00 
 0.00 
 8.61 
(11.48)
 76.00 
CMRA  5.99 (0.20) 0.00 (0.01) 0.00 
 0.00 
 13.95 
(12.70)
 30.28 
SABS  5.56  0.48  0.06  1.32  6.18 
(6.45)
 17.06 
(11.25)
 45.73 
PCSA  2.77 (0.67) 0.00 (0.41) 0.00 
 0.00 
 6.20 
(5.34)
 20.99 
FRTX  4.93  0.43  0.08  0.36  5.64 
(6.46)
 7.84 
(11.11)
 49.60 
THRD  3.39 (0.10) 0.01  0.08  4.83 
(3.30)
 8.35 
(6.74)
 25.76 
All Fundamental Data

Sqz Biotechnologies Competitive Analysis

The better you understand Sqz Biotechnologies competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Sqz Biotechnologies' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Sqz Biotechnologies' competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
SQZ ANTX MIRO IKT PMVP ANEB CMRA SABS PCSA FRTX
 28.57 
 0.10 
Sqz
 1.44 
 1.37 
AN2
 12.87 
 1.49 
Miromatrix
 15.68 
 2.73 
Inhibikase
 0.63 
 1.60 
Pmv
 2.14 
 1.43 
Anebulo
 1.54 
 0.66 
Comera
 0.67 
 2.95 
SAB
 3.92 
 0.98 
Processa
 10.34 
 0.78 
Fresh
Market Volatility
(90 Days Market Risk)
Very steady
Slightly risky
Very steady
Dangerous
Very risky
Dangerous
Very steady
Dangerous
Extremely Dangerous
Very steady
Market Performance
(90 Days Performance)
Very Weak
OK
Very Weak
Good
Weak
Very Weak
Very Weak
Insignificant
Very Weak
Very Weak
Odds of Financial Distress
(Probability Of Bankruptcy)
Dangerous
Average
Dangerous
Below Average
Average
Low
Dangerous
About Average
Very High
Dangerous
Current Valuation
(Equity Enterprise Value)
Over Valued
Under Valued
Over Valued
Over Valued
Over Valued
Under Valued
Over Valued
Over Valued
Over Valued
Over Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Buy
Not Available
Buy
Strong Buy
Strong Buy
Not Available
Strong Buy
Buy
Not Available
Trade Advice
(90 Days Macroaxis Advice)
Not Rated
Strong Hold
Not Rated
Cautious Hold
Sell
Strong Sell
Not Rated
Strong Sell
Strong Sell
Not Rated
Current Ratio
3.87
28.17
9.09
7.56
24.76
30.4
2.14
1.72
8.89
6.36
Net Asset
99.9 M
138.74 M
34.76 M
14.51 M
252.15 M
4.07 M
3.73 M
83.94 M
5.79 M
10.27 M
Profit Margin
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
-0.89
EBITDA
(59.28 M)
4.9 M
(29.91 M)
(19.91 M)
(78.88 M)
(8.05 M)
(13.33 M)
(38.08 M)
(11.46 M)
(21.09 M)
Operating Margin
-3.92
N/A
-593.69
-238.85
N/A
N/A
-15.82
-34.23
N/A
0.25
Current Valuation
(6.5 M)
(54.31 M)
80.11 M
180.34 M
(86.78 M)
35.68 M
9.96 M
1.35 M
407.31 K
(4.04 M)
Price To Book
0.5
0.47
5.98
26.46
0.42
19.53
N/A
0.74
0.86
0.45
Retained Earnings
(274.97 M)
(154.46 M)
(104.01 M)
(66.9 M)
(310 M)
(65.4 M)
(34.9 M)
(90.06 M)
(75.37 M)
(166.47 M)
Current Asset
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Beta
2.71
-0.22
0.015
1.12
1.48
-1.01
1.16
0.64
0.6
0.47
Number Of Employees
53
41
76
8
63
2
12
57
13
13
Shares Outstanding
29.49 M
29.88 M
27.42 M
67.19 M
51.75 M
25.93 M
30.74 M
9.23 M
3.27 M
5.97 M
Cash Flow From Operations
(83.55 M)
(53.29 M)
(26.68 M)
(18.09 M)
(55.66 M)
(8.09 M)
(9.77 M)
(25.12 M)
(8.06 M)
(19.34 M)
Annual Yield
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
0.0134
Total Debt
27.47 M
14.04 M
3.55 M
622 K
13.29 M
260.58 K
775.05 K
5.91 M
150.55 K
49 K
Return On Equity
-1.05
-0.69
-1.14
-1.5
-0.24
-1.14
-16.29
-1.75
-2.12
-0.81
Z Score
-4.76
N/A
9.47
N/A
N/A
N/A
-20.09
N/A
N/A
31.28
Return On Asset
-0.33
-0.43
-0.56
-0.76
-0.2
-0.66
-1.19
-0.79
-1.13
-0.42
Number Of Shares Shorted
811.15 K
379.6 K
11.66 K
305.66 K
846.9 K
6.51 K
281.55 K
39.93 K
73.06 K
50.18 K
Book Value Per Share
1.36
4.19
0.57
1.78
3.82
0.15
-0.14
4.0
1.14
1.85
Current Liabilities
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Total Asset
99.9 M
138.74 M
34.76 M
14.51 M
252.15 M
4.07 M
3.73 M
83.94 M
5.79 M
10.27 M
Debt To Equity
0.74
N/A
0.095
0.006
0.045
N/A
0.16
0.16
0.001
0.002
Short Ratio
27.26
0.82
0.03
0.17
3.93
1.94
0.84
0.29
2.42
0.69
Target Price
19.0
2.67
3.13
7.0
5.8
6.0
N/A
12.4
6.0
4.5
Shares Owned By Institutions
66.58
52.31
25.75
11.62
80.89
28.18
2.7
34.24
1.48
8.96
Market Capitalization
12.83 M
40.93 M
92.95 M
183.44 M
82.8 M
42.79 M
6.85 M
27.23 M
3.2 M
4.84 M
Price To Earnings To Growth
-0.03
N/A
N/A
N/A
-0.31
N/A
N/A
N/A
-0.12
N/A
Price To Earning
N/A
3.96
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Price To Sales
1.24
N/A
97.02
2305.34
N/A
N/A
43.28
18.0
N/A
0.48
Net Income
(79.46 M)
(64.73 M)
(29.96 M)
(19.03 M)
(68.96 M)
(8.2 M)
(18 M)
(42.19 M)
(11.12 M)
(21.1 M)
Earnings Per Share
-2.16
-1.99
-1.14
-3.12
-1.0
-0.32
-0.22
-6.3
-4.8
-2.32
Shares Owned By Insiders
3.12
21.63
23.95
10.46
2.3
64.22
51.33
19.15
8.74
11.62
Revenue
21.03 M
N/A
953.47 K
260.5 K
N/A
N/A
633.1 K
2.24 M
N/A
6.94 M
Working Capital
46.36 M
96.46 M
22.36 M
10.77 M
193.38 M
3.25 M
(2 M)
48.09 M
4.9 M
7.01 M
Cash And Equivalents
63.71 M
113.39 M
32.67 M
32.21 M
277.43 M
14.55 M
4.94 M
16.62 M
12.06 M
14.48 M
Cash Per Share
3.61
5.84
1.56
1.28
6.08
0.62
0.26
0.39
0.76
5.04
Gross Profit
(43.05 M)
N/A
(466.93 K)
(8.26 M)
N/A
N/A
422.71 K
(12.53 M)
N/A
(27.83 M)
Day Typical Price
0.11
1.39
1.56
2.66
1.61
1.48
0.65
2.98
0.99
0.81
Accumulation Distribution
0.36
0.0759
0.14
0.16
0.0305
0.1
0.0896
0.0895
0.0392
0.14
Market Facilitation Index
0.0499
0.11
0.24
0.47
0.05
0.16
0.06
0.28
0.04
0.12
Daily Balance Of Power
(0.80)
(0.18)
(0.92)
0.7872
0.2
0.1875
0.1667
(0.07)
(1.00)
(0.75)
Period Momentum Indicator
(0.04)
(0.02)
(0.22)
0.37
0.01
0.03
0.01
(0.02)
(0.04)
(0.09)
Rate Of Daily Change
0.71
0.99
0.87
1.16
1.01
1.02
1.02
0.99
0.96
0.9
Day Median Price
0.12
1.4
1.59
2.63
1.62
1.51
0.64
2.99
1.0
0.82
Price Action Indicator
(0.04)
(0.04)
(0.21)
0.29
(0.01)
(0.07)
0.025
(0.05)
(0.04)
(0.09)
Coefficient Of Variation
(702.26)
1209.19
1551.16
544.15
5101.98
(5,409)
(155,105)
1482.43
(781.95)
1321.54
Mean Deviation
6.92
1.86
4.85
4.73
1.55
5.0
5.99
5.56
2.77
4.93
Jensen Alpha
(2.20)
0.1902
0.379
1.03
(0.03)
(0.35)
(0.20)
0.4779
(0.67)
0.43
Total Risk Alpha
(4.07)
(0.25)
(0.60)
0.2127
(0.32)
(1.51)
(1.17)
(0.67)
(1.13)
(0.65)
Sortino Ratio
N/A
0.061
0.0521
0.1974
(0.03)
N/A
N/A
0.0638
N/A
0.076
Downside Variance
N/A
8.06
36.83
31.46
5.96
N/A
N/A
41.05
N/A
46.22
Standard Deviation
13.85
3.61
6.85
6.71
2.38
8.89
7.65
7.91
4.01
8.48
Kurtosis
12.26
22.74
2.54
1.28
3.25
14.19
0.1109
2.81
2.95
11.06
Potential Upside
5.26
3.73
11.73
14.93
3.75
8.61
13.95
17.06
6.2
7.84
Treynor Ratio
(1.05)
0.3385
0.9439
0.7333
0.0667
(0.12)
(0.01)
1.32
(0.41)
0.3612
Maximum Drawdown
103.87
28.03
38.49
37.4
13.98
76.0
30.28
45.73
20.99
49.6
Variance
191.93
13.03
46.97
44.99
5.68
78.98
58.52
62.63
16.08
71.93
Market Risk Adjusted Performance
(1.04)
0.3485
0.9539
0.7433
0.0767
(0.11)
8.0E-4
1.33
(0.40)
0.3712
Risk Adjusted Performance
(0.1)
0.0712
0.0583
0.1497
0.0218
(0.01)
0.0085
0.0607
(0.09)
0.0671
Skewness
2.19
3.79
0.9188
0.5176
0.811
1.93
0.287
1.03
0.4199
2.43
Semi Deviation
N/A
1.86
5.26
4.76
1.99
N/A
N/A
6.18
N/A
5.64
Information Ratio
(0.15)
0.048
0.0462
0.1651
(0.03)
(0.03)
(0.02)
0.0516
(0.16)
0.0609
Value At Risk
(23.08)
(3.42)
(8.87)
(9.09)
(3.64)
(11.48)
(12.70)
(11.25)
(5.34)
(11.11)
Expected Short fall
N/A
(3.09)
(6.37)
(5.60)
(1.87)
N/A
N/A
(6.45)
N/A
(6.46)
Downside Deviation
N/A
2.84
6.07
5.61
2.44
N/A
N/A
6.41
N/A
6.8
Semi Variance
N/A
3.44
27.65
22.65
3.98
N/A
N/A
38.16
N/A
31.82

Sqz Biotechnologies Competition Performance Charts

Five steps to successful analysis of Sqz Biotechnologies Competition

Sqz Biotechnologies' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Sqz Biotechnologies in relation to its competition. Sqz Biotechnologies' competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Sqz Biotechnologies in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Sqz Biotechnologies' competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Sqz Biotechnologies, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Sqz Biotechnologies position

In addition to having Sqz Biotechnologies in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Cancer Fighters Thematic Idea Now

Cancer Fighters
Cancer Fighters Theme
Biotech and medical diagnostic companies that work on researching drugs or manufacturing of medical and therapeutics equipment that is directly related to the research, treatment, and detection of cancer or cancer related diseases. The Cancer Fighters theme has 60 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Cancer Fighters Theme or any other thematic opportunities.
View All  Next Launch
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in producer price index.
You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.

Other Consideration for investing in Sqz Stock

If you are still planning to invest in Sqz Biotechnologies check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Sqz Biotechnologies' history and understand the potential risks before investing.
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
Transaction History
View history of all your transactions and understand their impact on performance
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Fundamental Analysis
View fundamental data based on most recent published financial statements
CEOs Directory
Screen CEOs from public companies around the world
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY